Mark A Rubin

List of Publications by Year in Descending Order

496 papers	67,812 citations	126 h-index	252 g-index
531 ext. papers	77,903 ext. citations	10.8 avg, IF	7.11 L-index

#	Paper	IF	Citations
496	What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021.. *European Urology*, **2022**,	10.2	2
495	Comparative genomics of primary prostate cancer and paired metastases: insights from 12 molecular case studies.. *Journal of Pathology*, **2022**,	9.4	1
494	Alterations in homologous recombination repair genes in prostate cancer brain metastases.. *Nature Communications*, **2022**, 13, 2400	17.4	3
493	The evolving landscape of prostate cancer somatic mutations. *Prostate*, **2022**, 82,	4.2	0
492	PARP Inhibition in Prostate Cancer With Homologous Recombination Repair Alterations. *JCO Precision Oncology*, **2021**, 5,	3.6	3
491	G3BP1 inhibits Cul3 to amplify AR signaling and promote prostate cancer. *Nature Communications*, **2021**, 12, 6662	17.4	3
490	Dynamic prostate cancer transcriptome analysis delineates the trajectory to disease progression. *Nature Communications*, **2021**, 12, 7033	17.4	4
489	Comparative pathology of dog and human prostate cancer. *Veterinary Medicine and Science*, **2021**,	2.1	5
488	Extracellular Matrix in Synthetic Hydrogel-Based Prostate Cancer Organoids Regulate Therapeutic Response to EZH2 and DRD2 Inhibitors. *Advanced Materials*, **2021**, e2100096	24	3
487	NKX3.1 Localization to Mitochondria Suppresses Prostate Cancer Initiation. *Cancer Discovery*, **2021**, 11, 2316-2333	24.4	8
486	Targeting the epichaperome as an effective precision medicine approach in a novel PML-SYK fusion acute myeloid leukemia. *Npj Precision Oncology*, **2021**, 5, 44	9.8	6
485	Prostate cancer patient-derived organoids: detailed outcome from a prospective cohort of 81 clinical specimens. *Journal of Pathology*, **2021**, 254, 543-555	9.4	7
484	Histological and immunohistochemical investigation of canine prostate carcinoma with identification of common intraductal carcinoma component. *Veterinary and Comparative Oncology*, **2021**,	2.5	3
483	PI5P4Ks drive metabolic homeostasis through peroxisome-mitochondria interplay. *Developmental Cell*, **2021**, 56, 1661-1676.e10	10.2	7
482	CD38 in Advanced Prostate Cancers. *European Urology*, **2021**, 79, 736-746	10.2	0
481	Mapping of mA and Its Regulatory Targets in Prostate Cancer Reveals a METTL3-Low Induction of Therapy Resistance. *Molecular Cancer Research*, **2021**, 19, 1398-1411	6.6	2
480	The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer. *Archives of Pathology and Laboratory Medicine*, **2021**, 145, 461-493	5	41

479	Practice patterns related to prostate cancer grading: results of a 2019 Genitourinary Pathology Society clinician survey. *Urologic Oncology: Seminars and Original Investigations*, **2021**, 39, 295.e1-295.e8	2.8	1
478	Loss and revival of androgen receptor signaling in advanced prostate cancer. *Oncogene*, **2021**, 40, 1205-1216	9.2	13
477	Prostate cancer hijacks the microenvironment. *Nature Cell Biology*, **2021**, 23, 3-5	23.4	6
476	Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer. *Nature Communications*, **2021**, 12, 734	17.4	10
475	Molecular medicine tumor board: whole-genome sequencing to inform on personalized medicine for a man with advanced prostate cancer. *Prostate Cancer and Prostatic Diseases*, **2021**, 24, 786-793	6.2	3
474	Patient-derived xenografts and organoids model therapy response in prostate cancer. *Nature Communications*, **2021**, 12, 1117	17.4	18
473	Co-occurrence and mutual exclusivity: what cross-cancer mutation patterns can tell us. *Trends in Cancer*, **2021**, 7, 823-836	12.5	3
472	The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer.. *Nature Communications*, **2021**, 12, 7349	17.4	10
471	Role of specialized composition of SWI/SNF complexes in prostate cancer lineage plasticity. *Nature Communications*, **2020**, 11, 5549	17.4	31
470	Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers. I. Molecular Biomarkers in Prostate Cancer. *American Journal of Surgical Pathology*, **2020**, 44, e15-e29	6.7	21
469	Fusions involving BCOR and CREBBP are rare events in infiltrating glioma. *Acta Neuropathologica Communications*, **2020**, 8, 80	7.3	3
468	Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT) beyond Mutations: A Comprehensive Genomic Analysis. *Cells*, **2020**, 9,	7.9	14
467	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. *European Urology*, **2020**, 77, 508-547	10.2	155
466	Pathway and network analysis of more than 2500 whole cancer genomes. *Nature Communications*, **2020**, 11, 729	17.4	38
465	Analyses of non-coding somatic drivers in 2,658 cancer whole genomes. *Nature*, **2020**, 578, 102-111	50.4	220
464	Integrative multiplatform molecular profiling of benign prostatic hyperplasia identifies distinct subtypes. *Nature Communications*, **2020**, 11, 1987	17.4	14
463	Performance Characteristics of a Targeted Sequencing Platform for Simultaneous Detection of Single Nucleotide Variants, Insertions/Deletions, Copy Number Alterations, and Gene Fusions in Cancer Genome. *Archives of Pathology and Laboratory Medicine*, **2020**, 144, 1535-1546	5	4
462	A MYC and RAS co-activation signature in localized prostate cancer drives bone metastasis and castration resistance. *Nature Cancer*, **2020**, 1, 1082-1096	15.4	18

461	Clinical deployment of AI for prostate cancer diagnosis. *The Lancet Digital Health*, **2020**, 2, e383-e384	14.4	3
460	Common germline-somatic variant interactions in advanced urothelial cancer. *Nature Communications*, **2020**, 11, 6195	17.4	6
459	Impact of Lineage Plasticity to and from a Neuroendocrine Phenotype on Progression and Response in Prostate and Lung Cancers. *Molecular Cell*, **2020**, 80, 562-577	17.6	12
458	Sex differences in oncogenic mutational processes. *Nature Communications*, **2020**, 11, 4330	17.4	23
457	SETting Up for Epigenetic Regulation of Advanced Prostate Cancer. *Cancer Cell*, **2020**, 38, 309-311	24.3	1
456	GRAM: A GeneRAlized Model to predict the molecular effect of a non-coding variant in a cell-type specific manner. *PLoS Genetics*, **2019**, 15, e1007860	6	1
455	Cancer-Specific Thresholds Adjust for Whole Exome Sequencing-based Tumor Mutational Burden Distribution. *JCO Precision Oncology*, **2019**, 3,	3.6	8
454	Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer. *JCO Precision Oncology*, **2019**, 3,	3.6	15
453	Genomic correlates of clinical outcome in advanced prostate cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2019**, 116, 11428-11436	11.5	383
452	Characterization of the ERG-regulated Kinome in Prostate Cancer Identifies TNIK as a Potential Therapeutic Target. *Neoplasia*, **2019**, 21, 389-400	6.4	10
451	CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis. *Cancer Cell*, **2019**, 35, 603-617.e8	24.3	29
450	DNA Hypermethylation Encroachment at CpG Island Borders in Cancer Is Predisposed by H3K4 Monomethylation Patterns. *Cancer Cell*, **2019**, 35, 297-314.e8	24.3	34
449	Proteomic and genomic signatures of repeat instability in cancer and adjacent normal tissues. *Proceedings of the National Academy of Sciences of the United States of America*, **2019**, 116, 16987-16996	11.5	6
448	The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance. *Clinical Cancer Research*, **2019**, 25, 6916-6924	12.9	94
447	Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling. *Nature Communications*, **2019**, 10, 2977	17.4	71
446	A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers. *Clinical Cancer Research*, **2019**, 25, 43-51	12.9	110
445	Prostate Cancer Research at the Crossroads. *Cold Spring Harbor Perspectives in Medicine*, **2019**, 9,	5.4	2
444	The Genomics of Prostate Cancer: A Historic Perspective. *Cold Spring Harbor Perspectives in Medicine*, **2019**, 9,	5.4	10

443	Rapid autopsy of a patient with recurrent anaplastic ependymoma. *Palliative and Supportive Care*, **2018**, 16, 238-242	2.5	2
442	Loss of an Androgen-Inactivating and Isoform-Specific HSD17B4 Splice Form Enables Emergence of Castration-Resistant Prostate Cancer. *Cell Reports*, **2018**, 22, 809-819	10.6	23
441	Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study. *European Urology*, **2018**, 73, 687-693	10.2	70
440	Bone biopsy protocol for advanced prostate cancer in the era of precision medicine. *Cancer*, **2018**, 124, 1008-1015	6.4	24
439	The Genomics of Prostate Cancer: emerging understanding with technologic advances. *Modern Pathology*, **2018**, 31, S1-11	9.8	31
438	Phosphatidylinositol-5-Phosphate 4-Kinases Regulate Cellular Lipid Metabolism By Facilitating Autophagy. *Molecular Cell*, **2018**, 70, 531-544.e9	17.6	35
437	The long tail of oncogenic drivers in prostate cancer. *Nature Genetics*, **2018**, 50, 645-651	36.3	380
436	Characterization of CD34-deficient myofibroblastomas of the breast. *Breast Journal*, **2018**, 24, 55-61	1.2	4
435	Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. *European Urology*, **2018**, 73, 178-211	10.2	313
434	SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity. *Clinical Cancer Research*, **2018**, 24, 5585-5593	12.9	74
433	Sequence of events in prostate cancer. *Nature*, **2018**, 560, 557-559	50.4	3
432	Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. *Nature*, **2018**, 560, 499-503	50.4	277
431	Patient derived organoids to model rare prostate cancer phenotypes. *Nature Communications*, **2018**, 9, 2404	17.4	149
430	Transcriptomic heterogeneity in multifocal prostate cancer. *JCI Insight*, **2018**, 3,	9.9	41
429	Differential impact of RB status on E2F1 reprogramming in human cancer. *Journal of Clinical Investigation*, **2018**, 128, 341-358	15.9	58
428	SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG. *Journal of Clinical Investigation*, **2018**, 128, 381-386	15.9	23
427	Upper tract urothelial carcinoma is non-basal and T-cell depleted.. *Journal of Clinical Oncology*, **2018**, 36, 4525-4525	2.2	1
426	Molecular and clinical implications of CHD1 loss and SPOP mutations in advanced prostate cancer.. *Journal of Clinical Oncology*, **2018**, 36, 5064-5064	2.2	2

425	Integrative molecular profiling challenges robustness of prognostic signature scores in multifocal prostate cancer.. *Journal of Clinical Oncology*, **2018**, 36, 96-96	2.2	1
424	Clinical outcome of patients with germline DNA repair mutations: Results from a retrospective international study.. *Journal of Clinical Oncology*, **2018**, 36, 218-218	2.2	
423	Targeting the Epichaperome As an Effective Precision Medicine Approach in a Novel PML-SYK Fusion Acute Myeloid Leukemia. *Blood*, **2018**, 132, 1435-1435	2.2	1
422	Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. *Journal of Clinical Oncology*, **2018**, 36, 2492-2503	2.2	271
421	Impact of the SPOP Mutant Subtype on the Interpretation of Clinical Parameters in Prostate Cancer. *JCO Precision Oncology*, **2018**, 2018,	3.6	17
420	Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. *Journal of Clinical Investigation*, **2018**, 128, 4441-4453	15.9	84
419	NSD2 is a conserved driver of metastatic prostate cancer progression. *Nature Communications*, **2018**, 9, 5201	17.4	44
418	TET2 Deficiency Causes Germinal Center Hyperplasia, Impairs Plasma Cell Differentiation, and Promotes B-cell Lymphomagenesis. *Cancer Discovery*, **2018**, 8, 1632-1653	24.4	77
417	Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses. *Nature Communications*, **2018**, 9, 3600	17.4	60
416	Prostate Power Play: Does Accelerate -Deficient Cancer Progression?. *Cancer Discovery*, **2018**, 8, 682-685	24.4	4
415	The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications. *GigaScience*, **2018**, 7,	7.6	35
414	SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. *Science*, **2017**, 355, 84-88	33.3	491
413	Racial Variation in the Utility of Urinary Biomarkers PCA3 and T2ERG in a Large Multicenter Study. *Journal of Urology*, **2017**, 198, 42-49	2.5	10
412	Non-coding genetic variation in cancer. *Current Opinion in Systems Biology*, **2017**, 1, 9-15	3.2	23
411	Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer. *Cancer Discovery*, **2017**, 7, 736-749	24.4	182
410	Transplantation of engineered organoids enables rapid generation of metastatic mouse models of colorectal cancer. *Nature Biotechnology*, **2017**, 35, 577-582	44.5	137
409	Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function Mutations. *Cancer Discovery*, **2017**, 7, 973-983	24.4	65
408	Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer. *JAMA Oncology*, **2017**, 3, 1085-1093	13.4	88

407	Prostate cancer: Clinical hallmarks in whole cancer genomes. *Nature Reviews Clinical Oncology*, **2017**, 14, 265-266	19.4	1
406	Personalized and Cancer Models to Guide Precision Medicine. *Cancer Discovery*, **2017**, 7, 462-477	24.4	477
405	SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling. *Cancer Cell*, **2017**, 31, 436-451	24.3	116
404	Quantification of mutant SPOP proteins in prostate cancer using mass spectrometry-based targeted proteomics. *Journal of Translational Medicine*, **2017**, 15, 175	8.5	5
403	Identification of novel prostate cancer drivers using RegNetDriver: a framework for integration of genetic and epigenetic alterations with tissue-specific regulatory network. *Genome Biology*, **2017**, 18, 141	18.3	20
402	Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models. *JCO Precision Oncology*, **2017**, 2017,	3.6	23
401	Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. *Nature Medicine*, **2017**, 23, 1063-1071	50.5	169
400	Aberrant Activation of a Gastrointestinal Transcriptional Circuit in Prostate Cancer Mediates Castration Resistance. *Cancer Cell*, **2017**, 32, 792-806.e7	24.3	39
399	A germline FANCA alteration that is associated with increased sensitivity to DNA damaging agents. *Journal of Physical Education and Sports Management*, **2017**, 3,	2.8	15
398	Inherited determinants of early recurrent somatic mutations in prostate cancer. *Nature Communications*, **2017**, 8, 48	17.4	16
397	The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer. *Cancer Discovery*, **2017**, 7, 54-71	24.4	173
396	The cancer precision medicine knowledge base for structured clinical-grade mutations and interpretations. *Journal of the American Medical Informatics Association: JAMIA*, **2017**, 24, 513-519	8.6	66
395	The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics. *European Urology*, **2017**, 71, 237-246	10.2	41
394	DNA Repair in Prostate Cancer: Biology and Clinical Implications. *European Urology*, **2017**, 71, 417-425	10.2	132
393	Re: Prognostic Significance of Percentage and Architectural Types of Contemporary Gleason Pattern 4 Prostate Cancer in Radical Prostatectomy. *European Urology*, **2017**, 71, 301	10.2	1
392	Biology and evolution of poorly differentiated neuroendocrine tumors. *Nature Medicine*, **2017**, 23, 1-10	50.5	109
391	On-site Cytology for Development of Patient-Derived Three-dimensional Organoid Cultures - A Pilot Study. *Anticancer Research*, **2017**, 37, 1569-1573	2.3	5
390	Punctuated evolution of copy-number alterations to define two molecular subtypes of muscle-invasive urothelial carcinoma.. *Journal of Clinical Oncology*, **2017**, 35, 299-299	2.2	

389	The long tail of significantly mutated genes in prostate cancer.. *Journal of Clinical Oncology*, **2017**, 35, 131-131	2.2	
388	Clonal evolution of chemotherapy-resistant urothelial carcinoma. *Nature Genetics*, **2016**, 48, 1490-1499	36.3	161
387	Development and validation of a whole-exome sequencing test for simultaneous detection of point mutations, indels and copy-number alterations for precision cancer care. *Npj Genomic Medicine*, **2016**, 1,	6.2	51
386	Prostate cancer risk regions at 8q24 and 17q24 are differentially associated with somatic TMPRSS2:ERG fusion status. *Human Molecular Genetics*, **2016**, 25, 5490-5499	5.6	6
385	A Computational Drug Repositioning Approach for Targeting Oncogenic Transcription Factors. *Cell Reports*, **2016**, 15, 2348-56	10.6	25
384	Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer. *JAMA Oncology*, **2016**, 2, 471-80	13.4	38
383	Role of non-coding sequence variants in cancer. *Nature Reviews Genetics*, **2016**, 17, 93-108	30.1	301
382	Genomic Correlates to the Newly Proposed Grading Prognostic Groups for Prostate Cancer. *European Urology*, **2016**, 69, 557-560	10.2	50
381	Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. *Nature Medicine* , **2016**, 22, 298-305	50.5	775
380	Clonal evaluation of prostate cancer foci in biopsies with discontinuous tumor involvement by dual ERG/SPINK1 immunohistochemistry. *Modern Pathology*, **2016**, 29, 157-65	9.8	25
379	Inherited mutations in DNA repair genes in men with metastatic castration-resistant prostate cancer.. *Journal of Clinical Oncology*, **2016**, 34, 5009-5009	2.2	1
378	Clinical and genomic characterization of metastatic small cell/neuroendocrine prostate cancer (SCNC) and intermediate atypical prostate cancer (IAC): Results from the SU2C/PCF/AACRWest Coast Prostate Cancer Dream Team (WCDT).. *Journal of Clinical Oncology*, **2016**, 34, 5019-5019	2.2	13
377	Generating a neoantigen map of advanced urothelial carcinoma by whole exome sequencing.. *Journal of Clinical Oncology*, **2016**, 34, 354-354	2.2	3
376	Serum Autoantibodies in Chronic Prostate Inflammation in Prostate Cancer Patients. *PLoS ONE*, **2016**, 11, e0147739	3.7	12
375	Integrated whole exome and RNA sequencing to reveal distinct genomic and transcriptomic landscape of upper tract urothelial carcinoma.. *Journal of Clinical Oncology*, **2016**, 34, 379-379	2.2	
374	Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. *New England Journal of Medicine*, **2016**, 375, 443-53	59.2	791
373	An emerging role for cytopathology in precision oncology. *Cancer Cytopathology*, **2016**, 124, 167-73	3.9	14
372	The Molecular Evolution of Castration-resistant Prostate Cancer. *European Urology Focus*, **2016**, 2, 506-513	5.1	23

371	Image-based computational quantification and visualization of genetic alterations and tumour heterogeneity. *Scientific Reports*, **2016**, 6, 24146	4.9	21
370	N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer. *Cancer Cell*, **2016**, 30, 563-577	24.3	256
369	Characterization of the leiomyomatous variant of myofibroblastoma: a rare subset distinct from other smooth muscle tumors of the breast. *Human Pathology*, **2016**, 58, 54-61	3.7	9
368	Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor Function. *Molecular Cell*, **2015**, 58, 925-34	14.6	102
367	Multicenter Evaluation of the Prostate Health Index to Detect Aggressive Prostate Cancer in Biopsy Naïve Men. *Journal of Urology*, **2015**, 194, 65-72	2.5	110
366	MAGI3-AKT3 fusion in breast cancer amended. *Nature*, **2015**, 520, E11-2	50.4	20
365	Genomics and Epigenomics of Prostate Cancer **2015**, 149-170		
364	Genomic rearrangements in prostate cancer. *Current Opinion in Urology*, **2015**, 25, 71-6	2.8	23
363	DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. *New England Journal of Medicine*, **2015**, 373, 1697-708	59.2	1345
362	The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer. *Cell Reports*, **2015**, 12, 922-36	10.6	155
361	Toward a prostate cancer precision medicine. *Urologic Oncology: Seminars and Original Investigations*, **2015**, 33, 73-4	2.8	7
360	Health: Make precision medicine work for cancer care. *Nature*, **2015**, 520, 290-1	50.4	45
359	SPOP mutation leads to genomic instability in prostate cancer. *ELife*, **2015**, 4,	8.9	110
358	Integrative clinical genomics of advanced prostate cancer. *Cell*, **2015**, 161, 1215-1228	56.2	1765
357	Functional characterization of BC039389-GATM and KLK4-KRSP1 chimeric read-through transcripts which are up-regulated in renal cell cancer. *BMC Genomics*, **2015**, 16, 247	4.5	11
356	Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response. *JAMA Oncology*, **2015**, 1, 466-74	13.4	207
355	Whole exome sequencing to reveal chemotherapy-driven evolution of platinum-resistant metastatic urothelial cancer.. *Journal of Clinical Oncology*, **2015**, 33, 4513-4513	2.2	1
354	Defining a molecular subclass of treatment resistant prostate cancer.. *Journal of Clinical Oncology*, **2015**, 33, 5004-5004	2.2	3

353	Phenotypic characterization of circulating tumor cells (CTCs) from neuroendocrine prostate cancer (NEPC) and metastatic castration-resistant prostate cancer (mCRPC) patients to identify a novel diagnostic algorithm for the presence of NEPC.. *Journal of Clinical Oncology*, **2015**, 33, 197-197	2.2	2
352	Precision medicine program for whole-exome sequencing (WES) provides new insight on platinum sensitivity in advanced prostate cancer (PCa).. *Journal of Clinical Oncology*, **2015**, 33, 158-158	2.2	1
351	Clonal heterogeneity in platinum-resistant metastatic urothelial cancer.. *Journal of Clinical Oncology*, **2015**, 33, 290-290	2.2	
350	SPOP mutations in prostate cancer across demographically diverse patient cohorts. *Neoplasia*, **2014**, 16, 14-20	6.4	113
349	PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. *Cancer Research*, **2014**, 74, 1651-60	10.1	204
348	TMPRSS2:ERG gene fusion predicts subsequent detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia. *Journal of Clinical Oncology*, **2014**, 32, 206-11	2.2	79
347	Insights into the mechanism of organ-specific cancer metastasis. *Cancer Discovery*, **2014**, 4, 1262-4	24.4	6
346	MYB-NFIB gene fusion in adenoid cystic carcinoma of the breast with special focus paid to the solid variant with basaloid features. *Human Pathology*, **2014**, 45, 2270-80	3.7	56
345	Prostate cancer. Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer. *Science*, **2014**, 346, 85-89	33.3	157
344	Prostate cancer with Paneth cell-like neuroendocrine differentiation has recognizable histomorphology and harbors AURKA gene amplification. *Human Pathology*, **2014**, 45, 2136-43	3.7	22
343	Organoid cultures derived from patients with advanced prostate cancer. *Cell*, **2014**, 159, 176-187	56.2	847
342	The lethal clone in prostate cancer: redefining the index. *European Urology*, **2014**, 66, 395-7	10.2	24
341	Association of oncofetal protein expression with clinical outcomes in patients with urothelial carcinoma of the bladder. *Journal of Urology*, **2014**, 191, 830-41	2.5	15
340	Aggressive variants of castration-resistant prostate cancer. *Clinical Cancer Research*, **2014**, 20, 2846-50	12.9	245
339	High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. *Cancer Research*, **2014**, 74, 1272-83	10.1	250
338	Consensus statement with recommendations on active surveillance inclusion criteria and definition of progression in men with localized prostate cancer: the critical role of the pathologist. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2014**, 465, 623-8	5.1	33
337	Unraveling the clonal hierarchy of somatic genomic aberrations. *Genome Biology*, **2014**, 15, 439	18.3	61
336	Evidence for molecular differences in prostate cancer between African American and Caucasian men. *Clinical Cancer Research*, **2014**, 20, 4925-34	12.9	108

335	The critical role of the pathologist in determining eligibility for active surveillance as a management option in patients with prostate cancer: consensus statement with recommendations supported by the College of American Pathologists, International Society of Urological Pathology, Association of Directors of Anatomic and Surgical Pathology, the New Zealand Society of [illegible]	5	99
334	ERG induces taxane resistance in castration-resistant prostate cancer. *Nature Communications*, **2014**, 5, 3554887-405	17.4	81
333	The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer. *Nature Communications*, **2014**, 5, 5383	17.4	432
332	Recurrent prostate cancer genomic alterations predict response to brachytherapy treatment. *Cancer Epidemiology Biomarkers and Prevention*, **2014**, 23, 594-600	4	25
331	Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. *American Journal of Surgical Pathology*, **2014**, 38, 756-67	6.7	305
330	A comparative study of ERG status assessment on DNA, mRNA, and protein levels using unique samples from a Swedish biopsy cohort. *Applied Immunohistochemistry and Molecular Morphology*, **2014**, 22, 136-41	1.9	12
329	Variants at IRX4 as prostate cancer expression quantitative trait loci. *European Journal of Human Genetics*, **2014**, 22, 558-63	5.3	27
328	Antibody-independent targeted quantification of TMPRSS2-ERG fusion protein products in prostate cancer. *Molecular Oncology*, **2014**, 8, 1169-80	7.9	20
327	Diagnostic utility of MYC amplification and anti-MYC immunohistochemistry in atypical vascular lesions, primary or radiation-induced mammary angiosarcomas, and primary angiosarcomas of other sites. *Human Pathology*, **2014**, 45, 709-16	3.7	85
326	HIT‐DRIVE: Multi-driver Gene Prioritization Based on Hitting Time. *Lecture Notes in Computer Science*, **2014**, 293-306	0.9	29
325	Frequent truncating mutations of the cohesin complex gene STAG2 in urothelial carcinoma of the bladder.. *Journal of Clinical Oncology*, **2014**, 32, 290-290	2.2	1
324	Molecular characterization of circulating tumor cells (CTCs) of patients with neuroendocrine prostate cancer (NEPC).. *Journal of Clinical Oncology*, **2014**, 32, 177-177	2.2	2
323	Development of novel metastatic prostate cancer cell lines by ‘organoid’ in vitro culture technology.. *Journal of Clinical Oncology*, **2014**, 32, 33-33	2.2	
322	Neuroendocrine Prostate Cancer **2013**, 277-282		4
321	Impact of constitutional copy number variants on biological pathway evolution. *BMC Evolutionary Biology*, **2013**, 13, 19	3	11
320	The mutational landscape of prostate cancer. *European Urology*, **2013**, 64, 567-76	10.2	144
319	Epigenomic alterations in localized and advanced prostate cancer. *Neoplasia*, **2013**, 15, 373-83	6.4	59
318	Integrative annotation of variants from 1092 humans: application to cancer genomics. *Science*, **2013** , 342, 1235587	33.3	281

317	Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. *Nature Biotechnology*, **2013**, 31, 1023-31	44.5	1353
316	Frequent truncating mutations of STAG2 in bladder cancer. *Nature Genetics*, **2013**, 45, 1428-30	36.3	139
315	Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. *Urologic Oncology: Seminars and Original Investigations*, **2013**, 31, 566-71	2.8	160
314	Novel MIR143-NOTCH fusions in benign and malignant glomus tumors. *Genes Chromosomes and Cancer*, **2013**, 52, 1075-87	5	99
313	Molecular archeology: unearthing androgen-induced structural rearrangements in prostate cancer genomes. *Cancer Cell*, **2013**, 23, 133-5	24.3	4
312	V-ets erythroblastosis virus E26 oncogene homolog (avian)/Trefoil factor 3/high-molecular-weight cytokeratin triple immunostain: a novel tissue-based biomarker in prostate cancer with potential clinical application. *Human Pathology*, **2013**, 44, 2282-92	3.7	7
311	Loss of SPINK1 expression is associated with unfavorable outcomes in urothelial carcinoma of the bladder after radical cystectomy. *Urologic Oncology: Seminars and Original Investigations*, **2013**, 31, 1716-24	2.8	13
310	Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. *Neoplasia*, **2013**, 15, 1-10	6.4	165
309	Identification of molecular tumor markers in renal cell carcinomas with TFE3 protein expression by RNA sequencing. *Neoplasia*, **2013**, 15, 1231-40	6.4	28
308	Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. *European Urology*, **2013**, 63, 920-6	10.2	313
307	Punctuated evolution of prostate cancer genomes. *Cell*, **2013**, 153, 666-77	56.2	862
306	Contemporary grading for prostate cancer: implications for patient care. *European Urology*, **2013**, 63, 892-901	10.2	69
305	Loss of SLC45A3 protein (prostein) expression in prostate cancer is associated with SLC45A3-ERG gene rearrangement and an unfavorable clinical course. *International Journal of Cancer*, **2013**, 132, 807-12	7.5	26
304	Novel dual-color immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma. *Modern Pathology*, **2013**, 26, 835-48	9.8	42
303	Turkey must end violent response to protests. *Science*, **2013**, 341, 236	33.3	2
302	Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma. *Genes Chromosomes and Cancer*, **2013**, 52, 775-84	5	349
301	Somatic copy number alterations by whole-exome sequencing implicates YWHAZ and PTK2 in castration-resistant prostate cancer. *Journal of Pathology*, **2013**, 231, 505-16	9.4	28
300	Recurrent NCOA2 gene rearrangements in congenital/infantile spindle cell rhabdomyosarcoma. *Genes Chromosomes and Cancer*, **2013**, 52, 538-50	5	143

299	Re: Stoehr et al. Lack of evidence for frequent MED12 p.L1224F mutation in prostate tumours from Caucasian patients. J Pathol 2013; 230: 453-456. *Journal of Pathology*, **2013**, 231, 271	9.4	1
298	Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 6997-7002	11.5	176
297	New strategies in prostate cancer: translating genomics into the clinic. *Clinical Cancer Research*, **2013**, 19, 517-23	12.9	47
296	Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression. *Cancer Research*, **2013**, 73, 1232-44	10.1	137
295	A phase II trial of the aurora kinase A inhibitor MLN8237 in patients with metastatic castrate resistant and neuroendocrine prostate cancer.. *Journal of Clinical Oncology*, **2013**, 31, TPS5096-TPS5096	2.2	4
294	Transcriptional regulation and prostate cancer risk loci.. *Journal of Clinical Oncology*, **2013**, 31, 1554-1554	2.2	
293	Targeted genomic sequencing of pediatric Burkitt lymphoma identifies recurrent alterations in antiapoptotic and chromatin-remodeling genes. *Blood*, **2012**, 120, 5181-4	2.2	84
292	Role of transcriptional corepressor CtBP1 in prostate cancer progression. *Neoplasia*, **2012**, 14, 905-14	6.4	49
291	Beyond PSA: the next generation of prostate cancer biomarkers. *Science Translational Medicine*, **2012**, 4, 127rv3	17.5	313
290	Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation. *Cancer Discovery*, **2012**, 2, 1024-35	24.4	107
289	Large oncosomes in human prostate cancer tissues and in the circulation of mice with metastatic disease. *American Journal of Pathology*, **2012**, 181, 1573-84	5.8	249
288	Oncogenic transcription factors as master regulators of chromatin topology: a new role for ERG in prostate cancer. *Cell Cycle*, **2012**, 11, 3380-3	4.7	12
287	Methylacyl-CoA racemase expression and lethal prostate cancer in the Physicians' Health Study and Health Professionals Follow-up Study. *Prostate*, **2012**, 72, 301-6	4.2	6
286	Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. *Nature Genetics*, **2012**, 44, 685-9	36.3	1079
285	From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. *Journal of Pathology*, **2012**, 227, 286-97	9.4	142
284	Selective detection of histologically aggressive prostate cancer: an Early Detection Research Network Prediction model to reduce unnecessary prostate biopsies with validation in the Prostate Cancer Prevention Trial. *Cancer*, **2012**, 118, 2651-8	6.4	16
283	Molecular genetics of prostate cancer: emerging appreciation of genetic complexity. *Histopathology*, **2012**, 60, 187-98	7.3	49
282	Multiphoton microscopy in the evaluation of human bladder biopsies. *Archives of Pathology and Laboratory Medicine*, **2012**, 136, 517-26	5	44

281	Common structural and epigenetic changes in the genome of castration-resistant prostate cancer. *Cancer Research*, **2012**, 72, 616-25	10.1	97
280	Next generation sequencing of prostate cancer from a patient identifies a deficiency of methylthioadenosine phosphorylase, an exploitable tumor target. *Molecular Cancer Therapeutics*, **2012**, 11, 775-83	6.1	30
279	Next-generation prostate cancer biobanking: toward a processing protocol amenable for the International Cancer Genome Consortium. *Diagnostic Molecular Pathology*, **2012**, 21, 61-8		25
278	Oncogene-mediated alterations in chromatin conformation. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 9083-8	11.5	110
277	Identification of functionally active, low frequency copy number variants at 15q21.3 and 12q21.31 associated with prostate cancer risk. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 6686-91	11.5	42
276	Challenges in recognizing treatment-related neuroendocrine prostate cancer. *Journal of Clinical Oncology*, **2012**, 30, e386-9	2.2	146
275	ETS rearrangements in prostate cancer. *Asian Journal of Andrology*, **2012**, 14, 393-9	2.8	17
274	Association of concurrent AURKA and MYCN amplification in primary prostate adenocarcinoma with the development of lethal neuroendocrine prostate cancer (NEPC).. *Journal of Clinical Oncology*, **2012**, 30, 120-120	2.2	
273	Identifying cancer mutations in neuroendocrine prostate cancer (NEPC) through massively parallel DNA sequencing of formalin-fixed paraffin-embedded (FFPE) tissue.. *Journal of Clinical Oncology*, **2012**, 30, 110-110	2.2	
272	Targeted next-generation sequencing (NGS) of advanced prostate cancer (PCA) using formalin-fixed tissue.. *Journal of Clinical Oncology*, **2012**, 30, 4649-4649	2.2	
271	Novel Genomic Alterations in MCL1 and ARID1A Identified in Pediatric Burkitt Lymphoma Using Targeted High-Throughput Sequencing. *Blood*, **2012**, 120, 899-899	2.2	
270	Frequency and clinicopathologic correlates of KRAS amplification in non-small cell lung carcinoma. *Lung Cancer*, **2011**, 74, 118-23	5.9	35
269	Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. *Cancer Discovery*, **2011**, 1, 487-95	24.4	550
268	DNA unwinding by ASCC3 helicase is coupled to ALKBH3-dependent DNA alkylation repair and cancer cell proliferation. *Molecular Cell*, **2011**, 44, 373-84	17.6	129
267	Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma. *Science Translational Medicine*, **2011**, 3, 98ra82	17.5	252
266	The diagnostic utility of novel immunohistochemical marker ERG in the workup of prostate biopsies with "atypical glands suspicious for cancer". *American Journal of Surgical Pathology*, **2011**, 35, 608-14	6.7	53
265	Transforming growth factor β receptor II protein expression in benign prostatic hyperplasia is associated with prostate volume and inflammation. *BJU International*, **2011**, 108, E23-8	5.6	24
264	Multiphoton microscopy for structure identification in human prostate and periprostatic tissue: implications in prostate cancer surgery. *BJU International*, **2011**, 108, 1421-9	5.6	46

263	Relevance of cohort design for studying the frequency of the ERG rearrangement in prostate cancer. *Histopathology*, **2011**, 58, 1028-36	7.3	30
262	Testing mutual exclusivity of ETS rearranged prostate cancer. *Laboratory Investigation*, **2011**, 91, 404-12	5.9	57
261	The genomic complexity of primary human prostate cancer. *Nature*, **2011**, 470, 214-20	50.4	984
260	Biobanking after robotic-assisted radical prostatectomy: a quality assessment of providing prostate tissue for RNA studies. *Journal of Translational Medicine*, **2011**, 9, 121	8.5	20
259	TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients. *Prostate*, **2011**, 71, 489-97	4.2	198
258	Common gene rearrangements in prostate cancer. *Journal of Clinical Oncology*, **2011**, 29, 3659-68	2.2	231
257	AlleleSeq: analysis of allele-specific expression and binding in a network framework. *Molecular Systems Biology*, **2011**, 7, 522	12.2	228
256	Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing. *Genome Research*, **2011**, 21, 56-67	9.7	156
255	Single focus prostate cancer: pathological features and ERG fusion status. *Journal of Urology*, **2011**, 185, 489-94	2.5	14
254	Validation of a TFE3 break-apart FISH assay for Xp11.2 translocation renal cell carcinomas. *Diagnostic Molecular Pathology*, **2011**, 20, 129-37		53
253	mRNA expression signature of Gleason grade predicts lethal prostate cancer. *Journal of Clinical Oncology*, **2011**, 29, 2391-6	2.2	119
252	SOX2 gene amplification and protein overexpression are associated with better outcome in squamous cell lung cancer. *Modern Pathology*, **2011**, 24, 944-53	9.8	153
251	Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. *Science Translational Medicine*, **2011**, 3, 94ra72	17.5	281
250	Characterization of KRAS rearrangements in metastatic prostate cancer. *Cancer Discovery*, **2011**, 1, 35-43	24.4	83
249	The landscape of somatic copy-number alteration across human cancers. *Nature*, **2010**, 463, 899-905	50.4	2590
248	Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. *Nature Medicine*, **2010**, 16, 793-8	50.5	382
247	Visual cues as a surrogate for tactile feedback during robotic-assisted laparoscopic prostatectomy: posterolateral margin rates in 1340 consecutive patients. *BJU International*, **2010**, 106, 528-36	5.6	41
246	Anatomical retro-apical technique of synchronous (posterior and anterior) urethral transection: a novel approach for ameliorating apical margin positivity during robotic radical prostatectomy. *BJU International*, **2010**, 106, 1364-73	5.6	52

245	An oncogenic role for ETV1 in melanoma. *Cancer Research*, **2010**, 70, 2075-84	10.1	94
244	Genetic variation of genes involved in dihydrotestosterone metabolism and the risk of prostate cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2010**, 19, 229-39	4	42
243	Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort. *Modern Pathology*, **2010**, 23, 539-46	9.8	116
242	ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor. *Modern Pathology*, **2010**, 23, 1061-7	9.8	97
241	FusionSeq: a modular framework for finding gene fusions by analyzing paired-end RNA-sequencing data. *Genome Biology*, **2010**, 11, R104	18.3	121
240	ERG rearrangement metastasis patterns in locally advanced prostate cancer. *Urology*, **2010**, 75, 762-7	1.6	51
239	Antibody-based detection of ERG rearrangement-positive prostate cancer. *Neoplasia*, **2010**, 12, 590-8	6.4	281
238	ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression. *Neoplasia*, **2010**, 12, 1031-40	6.4	46
237	ERG rearrangement is present in a subset of transition zone prostatic tumors. *Modern Pathology*, **2010**, 23, 1499-506	9.8	44
236	Molecular sampling of prostate cancer: a dilemma for predicting disease progression. *BMC Medical Genomics*, **2010**, 3, 8	3.7	169
235	Human prostate sphere-forming cells represent a subset of basal epithelial cells capable of glandular regeneration in vivo. *Prostate*, **2010**, 70, 491-501	4.2	115
234	Identification of the transcription factor single-minded homologue 2 as a potential biomarker and immunotherapy target in prostate cancer. *Clinical Cancer Research*, **2009**, 15, 5794-802	12.9	130
233	Oncosome formation in prostate cancer: association with a region of frequent chromosomal deletion in metastatic disease. *Cancer Research*, **2009**, 69, 5601-9	10.1	272
232	Aberrant cytoplasmic expression of p63 and prostate cancer mortality. *Cancer Epidemiology Biomarkers and Prevention*, **2009**, 18, 595-600	4	49
231	Heterogeneous nuclear ribonucleoprotein K is a novel regulator of androgen receptor translation. *Cancer Research*, **2009**, 69, 2210-8	10.1	49
230	Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. *Cancer Research*, **2009**, 69, 4674-81	10.1	327
229	Amplification of chromosomal segment 4q12 in non-small cell lung cancer. *Cancer Biology and Therapy*, **2009**, 8, 2042-50	4.6	65
228	Human bladder cancer diagnosis using Multiphoton microscopy. *Proceedings of SPIE*, **2009**, 7161,	1.7	28

227	SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer. *Cancer Research*, **2009**, 69, 2734-8	10.1	151
226	Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. *Clinical Cancer Research*, **2009**, 15, 4706-11	12.9	181
225	In situ evidence of KRAS amplification and association with increased p21 levels in non-small cell lung carcinoma. *American Journal of Clinical Pathology*, **2009**, 132, 500-5	1.9	21
224	Predisposition for TMPRSS2-ERG fusion in prostate cancer by variants in DNA repair genes. *Cancer Epidemiology Biomarkers and Prevention*, **2009**, 18, 3030-5	4	43
223	Genome-wide linkage analysis of TMPRSS2-ERG fusion in familial prostate cancer. *Cancer Research*, **2009**, 69, 640-6	10.1	25
222	Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3?. *Journal of Clinical Oncology*, **2009**, 27, 3459-64	22	276
221	Clinical significance of TTF-1 protein expression and TTF-1 gene amplification in lung adenocarcinoma. *Journal of Cellular and Molecular Medicine*, **2009**, 13, 1977-1986	5.6	86
220	Retinoid metabolism and ALDH1A2 (RALDH2) expression are altered in the transgenic adenocarcinoma mouse prostate model. *Biochemical Pharmacology*, **2009**, 78, 1127-38	6	34
219	ETS gene fusions in prostate cancer: from discovery to daily clinical practice. *European Urology*, **2009**, 56, 275-86	10.2	279
218	Distinct genomic aberrations associated with ERG rearranged prostate cancer. *Genes Chromosomes and Cancer*, **2009**, 48, 366-80	5	72
217	TMPRSS2-ERG gene fusions are infrequent in prostatic ductal adenocarcinomas. *Modern Pathology*, **2009**, 22, 1398-9; author reply 1399-40	9.8	4
216	Immunohistochemical and clinicopathological correlation of the metastasis-associated gene 1 (MTA1) expression in benign and malignant pancreatic endocrine tumors. *Modern Pathology*, **2009**, 22, 933-9	9.8	23
215	Tomlins et al. reply. *Nature*, **2009**, 457, E2-E3	50.4	5
214	SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. *Nature Genetics*, **2009**, 41, 1238-42	36.3	733
213	Integration of ERG gene mapping and gene-expression profiling identifies distinct categories of human prostate cancer. *BJU International*, **2009**, 103, 1293; author reply 1293	5.6	
212	Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy. *Cancer Research*, **2009**, 69, 4434-42	10.1	162
211	Pathway biomarker profiling of localized and metastatic human prostate cancer reveal metastatic and prognostic signatures. *Journal of Proteome Research*, **2009**, 8, 3044-54	5.6	51
210	Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. *Cell*, **2009**, 138, 245-56	56.2	691

209	Detection of TMPRSS2-ERG fusion gene expression in prostate cancer specimens by a novel assay using branched DNA. *Urology*, **2009**, 74, 1156-61	1.6	12
208	Validation in a multiple urology practice cohort of the Prostate Cancer Prevention Trial calculator for predicting prostate cancer detection. *Journal of Urology*, **2009**, 182, 2653-8	2.5	48
207	N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer. *Neoplasia*, **2009**, 11, 804-11	6.4	92
206	RHAMM (CD168) is overexpressed at the protein level and may constitute an immunogenic antigen in advanced prostate cancer disease. *Neoplasia*, **2009**, 11, 956-63	6.4	58
205	Diagnosis of NUT midline carcinoma using a NUT-specific monoclonal antibody. *American Journal of Surgical Pathology*, **2009**, 33, 984-91	6.7	277
204	Profiling critical cancer gene mutations in clinical tumor samples. *PLoS ONE*, **2009**, 4, e7887	3.7	295
203	Targeted therapy of cancer: new roles for pathologists--prostate cancer. *Modern Pathology*, **2008**, 21 Suppl 2, S44-55	9.8	37
202	A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis. *Modern Pathology*, **2008**, 21, 1056; author reply 1056-7	9.8	2
201	The role of SPINK1 in ETS rearrangement-negative prostate cancers. *Cancer Cell*, **2008**, 13, 519-28	24.3	254
200	Evaluating localized prostate cancer and identifying candidates for focal therapy. *Urology*, **2008**, 72, S12-24	2.6	101
199	Molecular and cytogenetic characterization of plexiform leiomyomata provide further evidence for genetic heterogeneity underlying uterine fibroids. *American Journal of Pathology*, **2008**, 172, 1403-10	5.8	22
198	Association of cytokeratin 7 and 19 expression with genomic stability and favorable prognosis in clear cell renal cell cancer. *International Journal of Cancer*, **2008**, 123, 569-76	7.5	32
197	A comprehensive approach toward novel serum biomarkers for benign prostatic hyperplasia: the MPSA Consortium. *Journal of Urology*, **2008**, 179, 1243-56	2.5	12
196	Role of the TMPRSS2-ERG gene fusion in prostate cancer. *Neoplasia*, **2008**, 10, 177-88	6.4	522
195	Golgi protein GOLM1 is a tissue and urine biomarker of prostate cancer. *Neoplasia*, **2008**, 10, 1285-94	6.4	74
194	EML4-ALK fusion lung cancer: a rare acquired event. *Neoplasia*, **2008**, 10, 298-302	6.4	201
193	SNP panel identification assay (SPIA): a genetic-based assay for the identification of cell lines. *Nucleic Acids Research*, **2008**, 36, 2446-56	20.1	54
192	Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. *Cancer Research*, **2008**, 68, 3584-90	10.1	220

191	Caveolin-1 interacts with a lipid raft-associated population of fatty acid synthase. *Cell Cycle*, **2008**, 7, 2257-67	4.7	69
190	Nine-gene molecular signature is not associated with prostate cancer death in a watchful waiting cohort. *Cancer Epidemiology Biomarkers and Prevention*, **2008**, 17, 249-51	4	12
189	Testing a multigene signature of prostate cancer death in the Swedish Watchful Waiting Cohort. *Cancer Epidemiology Biomarkers and Prevention*, **2008**, 17, 1682-8	4	17
188	Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. *Journal of the National Cancer Institute*, **2008**, 100, 815-25	9.7	251
187	BPH gene expression profile associated to prostate gland volume. *Diagnostic Molecular Pathology*, **2008**, 17, 207-13		23
186	Detection of early prostate cancer using a hepsin-targeted imaging agent. *Cancer Research*, **2008**, 68, 2286-91	10.1	92
185	Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications. *Clinical Cancer Research*, **2008**, 14, 3380-5	12.9	177
184	An illustration of the potential for mapping MRI/MRS parameters with genetic over-expression profiles in human prostate cancer. *Magnetic Resonance Materials in Physics, Biology, and Medicine*, **2008**, 21, 411-21	2.8	22
183	Partially circumventing peripheral tolerance for oncogene-specific prostate cancer immunotherapy. *Prostate*, **2008**, 68, 715-27	4.2	3
182	KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis. *Journal of Clinical Investigation*, **2008**, 118, 2711-21	15.9	89
181	New Perspectives in Prediction of Clinical Outcome of Prostate Cancer **2008**, 309-321		
180	Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model. *Neoplasia*, **2007**, 9, 200-6	6.4	104
179	Tissue-preserving approach to extracting DNA from paraffin-embedded specimens using tissue microarray technology. *Head and Neck*, **2007**, 29, 465-71	4.2	16
178	Integrative molecular concept modeling of prostate cancer progression. *Nature Genetics*, **2007**, 39, 41-51	36.3	734
177	High-throughput oncogene mutation profiling in human cancer. *Nature Genetics*, **2007**, 39, 347-51	36.3	847
176	The pro-apoptotic kinase Mst1 and its caspase cleavage products are direct inhibitors of Akt1. *EMBO Journal*, **2007**, 26, 4523-34	13	107
175	Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. *Modern Pathology*, **2007**, 20, 538-44	9.8	250
174	Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. *Nature*, **2007**, 448, 595-9	50.4	654

173	Characterizing the cancer genome in lung adenocarcinoma. *Nature*, **2007**, 450, 893-8	50.4	900
172	A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer. *BJU International*, **2007**, 100, 765-9	5.6	54
171	The phosphoinositide kinase PIKfyve mediates epidermal growth factor receptor trafficking to the nucleus. *Cancer Research*, **2007**, 67, 9229-37	10.1	55
170	Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 20007-12	11.5	812
169	Integrative microarray analysis of pathways dysregulated in metastatic prostate cancer. *Cancer Research*, **2007**, 67, 10296-303	10.1	64
168	Integrative analysis of genomic aberrations associated with prostate cancer progression. *Cancer Research*, **2007**, 67, 8229-39	10.1	96
167	Collagen XXIII expression is associated with prostate cancer recurrence and distant metastases. *Clinical Cancer Research*, **2007**, 13, 2634-42	12.9	29
166	TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. *American Journal of Surgical Pathology*, **2007**, 31, 882-8	6.7	351
165	TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications. *Urology*, **2007**, 70, 630-3	1.6	131
164	Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. *Human Pathology*, **2007**, 38, 696-701	3.7	326
163	Automated immunofluorescence analysis defines microvessel area as a prognostic parameter in clear cell renal cell cancer. *Human Pathology*, **2007**, 38, 1454-62	3.7	41
162	TMPRSS2-ETS fusion prostate cancer: biological and clinical implications. *Journal of Clinical Pathology*, **2007**, 60, 1185-6	3.9	41
161	Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. *Journal of Urology*, **2007**, 178, 2260-7	2.5	275
160	A preliminary study of JM-27: a serum marker that can specifically identify men with symptomatic benign prostatic hyperplasia. *Journal of Urology*, **2007**, 177, 610-4; discussion 614	2.5	12
159	A proposal on the identification, histologic reporting, and implications of intraductal prostatic carcinoma. *Archives of Pathology and Laboratory Medicine*, **2007**, 131, 1103-9	5	87
158	Development of an integrated prostate cancer research information system. *Clinical Genitourinary Cancer*, **2006**, 5, 61-6	3.3	50
157	A hierarchical Naïve Bayes Model for handling sample heterogeneity in classification problems: an application to tissue microarrays. *BMC Bioinformatics*, **2006**, 7, 514	3.6	45
156	Inferring loss-of-heterozygosity from unpaired tumors using high-density oligonucleotide SNP arrays. *PLoS Computational Biology*, **2006**, 2, e41	5	124

155	TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. *Cancer Research*, **2006**, 66, 8337-41	10.1	419
154	Elevated E2F1 inhibits transcription of the androgen receptor in metastatic hormone-resistant prostate cancer. *Cancer Research*, **2006**, 66, 11897-906	10.1	83
153	Application of oligonucleotide microarrays to assess the biological effects of neoadjuvant imatinib mesylate treatment for localized prostate cancer. *Clinical Cancer Research*, **2006**, 12, 152-8	12.9	23
152	Activation of beta-catenin signaling in prostate cancer by peptidyl-prolyl isomerase Pin1-mediated abrogation of the androgen receptor-beta-catenin interaction. *Molecular and Cellular Biology*, **2006**, 26, 929-39	4.8	57
151	Defining aggressive prostate cancer using a 12-gene model. *Neoplasia*, **2006**, 8, 59-68	6.4	73
150	Integrative biology of prostate cancer progression. *Annual Review of Pathology: Mechanisms of Disease*, **2006**, 1, 243-71	34	48
149	ADAM15 disintegrin is associated with aggressive prostate and breast cancer disease. *Neoplasia*, **2006**, 8, 319-29	6.4	73
148	Genomic profiling of hormone-naïve lymph node metastases in patients with prostate cancer. *Neoplasia*, **2006**, 8, 1083-9	6.4	18
147	Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. *Neoplasia*, **2006**, 8, 885-8	6.4	174
146	How well does the Gleason score predict prostate cancer death? A 20-year followup of a population based cohort in Sweden. *Journal of Urology*, **2006**, 175, 1337-40	2.5	112
145	Whole transcriptome amplification for gene expression profiling and development of molecular archives. *Neoplasia*, **2006**, 8, 153-62	6.4	38
144	TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. *Cancer Research*, **2006**, 66, 3396-400	10.1	387
143	Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. *Cancer Research*, **2006**, 66, 2815-25	10.1	830
142	Prognostic factors in lymph node-positive prostate cancer. *Urology*, **2006**, 67, 1016-21	1.6	37
141	A working group classification of focal prostate atrophy lesions. *American Journal of Surgical Pathology*, **2006**, 30, 1281-91	6.7	97
140	Characterization of ZAG protein expression in prostate cancer using a semi-automated microscope system. *Prostate*, **2006**, 66, 1037-43	4.2	39
139	Bioinformatics approach leads to the discovery of the TMPRSS2:ETS gene fusion in prostate cancer. *Laboratory Investigation*, **2006**, 86, 1099-102	5.9	28
138	Saturation biopsy protocol enhances prediction of pT3 and surgical margin status on prostatectomy specimen. *World Journal of Urology*, **2006**, 24, 676-80	4	27

137	Comprehensive analysis of the expression of the metastasis-associated gene 1 in human neoplastic tissue. *Archives of Pathology and Laboratory Medicine*, **2006**, 130, 989-96	5	27
136	Autoantibody signatures in prostate cancer. *New England Journal of Medicine*, **2005**, 353, 1224-35	59.2	521
135	Intertubular growth in pure seminomas: associations with poor prognostic parameters. *Human Pathology*, **2005**, 36, 640-5	3.7	20
134	Benign positive margins after radical prostatectomy means a poor prognosis--con. *Urology*, **2005**, 65, 221-3	1.6	2
133	Predictors of short postoperative prostate-specific antigen doubling time for patients diagnosed during PSA era. *Urology*, **2005**, 65, 528-32	1.6	14
132	Effects of long-term finasteride treatment on prostate cancer morphology and clinical outcome. *Urology*, **2005**, 66, 930-4	1.6	37
131	Molecular profiling of human prostate tissues: insights into gene expression patterns of prostate development during puberty. *FASEB Journal*, **2005**, 19, 243-5	0.9	76
130	Current thoughts on the role of the androgen receptor and prostate cancer progression. *Advances in Anatomic Pathology*, **2005**, 12, 265-70	5.1	19
129	Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. *Science*, **2005**, 310, 644-8	33.3	3022
128	Tissue-print and print-phoresis as platform technologies for the molecular analysis of human surgical specimens: mapping tumor invasion of the prostate capsule. *Nature Medicine*, **2005**, 11, 95-101	50.5	29
127	Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. *Nature*, **2005**, 436, 117-22	50.4	1127
126	Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. *Cancer Cell*, **2005**, 8, 393-406	24.3	625
125	What information are urologists extracting from prostate needle biopsy reports and what do they need for clinical management of prostate cancer?. *European Urology*, **2005**, 48, 911-5	10.2	39
124	Internet-based Profiler system as integrative framework to support translational research. *BMC Bioinformatics*, **2005**, 6, 304	3.6	8
123	PAR1-mediated NFkappaB activation promotes survival of prostate cancer cells through a Bcl-xL-dependent mechanism. *Journal of Cellular Biochemistry*, **2005**, 96, 641-52	4.7	72
122	Amplification and overexpression of prosaposin in prostate cancer. *Genes Chromosomes and Cancer*, **2005**, 44, 351-64	5	42
121	Molecular prostate cancer pathology: current issues and achievements. *Scandinavian Journal of Urology and Nephrology*, **2005**, 82-93		13
120	Identification of two molecular groups of seminomas by using expression and tissue microarrays. *Clinical Cancer Research*, **2005**, 11, 5722-9	12.9	30

119	Reg IV: a promising marker of hormone refractory metastatic prostate cancer. *Clinical Cancer Research*, **2005**, 11, 2237-43	12.9	43
118	Alpha-methylacyl-CoA racemase protein expression is associated with the degree of differentiation in breast cancer using quantitative image analysis. *Cancer Epidemiology Biomarkers and Prevention*, **2005**, 14, 1418-23	4	45
117	Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. *Cancer Research*, **2005**, 65, 5561-70	10.1	285
116	Decreased alpha-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death. *Cancer Epidemiology Biomarkers and Prevention*, **2005**, 14, 1424-32	4	92
115	Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer. *Journal of Clinical Oncology*, **2005**, 23, 1332-3; author reply 1333-4	2.2	4
114	A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. *Cancer Research*, **2005**, 65, 1213-22	10.1	182
113	Identification of leukocyte E-selectin ligands, P-selectin glycoprotein ligand-1 and E-selectin ligand-1, on human metastatic prostate tumor cells. *Cancer Research*, **2005**, 65, 5750-60	10.1	96
112	Translational crossroads for biomarkers. *Clinical Cancer Research*, **2005**, 11, 6103-8	12.9	64
111	Constructing tissue microarrays for research use. *Current Protocols in Human Genetics*, **2004**, Chapter 10, Unit 10.7	3.2	8
110	Molecular profiling and the identification of genes associated with metastatic oral cavity/pharynx squamous cell carcinoma. *JAMA Otolaryngology*, **2004**, 130, 295-302		95
109	The role of metastasis-associated protein 1 in prostate cancer progression. *Cancer Research*, **2004**, 64, 825-9	10.1	116
108	Usefulness of Basal Cell Cocktail (34Ë12 + p63) in the Diagnosis of Atypical Prostate Glandular Proliferations. *American Journal of Clinical Pathology*, **2004**, 122, 517-523	1.9	72
107	Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer. *Cancer Research*, **2004**, 64, 3814-22	10.1	136
106	JAGGED1 expression is associated with prostate cancer metastasis and recurrence. *Cancer Research* , **2004**, 64, 6854-7	10.1	280
105	Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. *Cancer Research*, **2004**, 64, 9209-16	10.1	712
104	Molecular genetics of human prostate cancer. *Modern Pathology*, **2004**, 17, 380-8	9.8	34
103	Effect of finasteride on risk of prostate cancer: how little we really know. *Journal of Cellular Biochemistry*, **2004**, 91, 478-82	4.7	11
102	Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer. *Journal of the National Cancer Institute*, **2004**, 96, 834-43	9.7	113

101	Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. *Human Molecular Genetics*, **2004**, 13, 1303-13	5.6	158
100	Fourth International Conference on Innovations and Challenges in Prostate Cancer: Prevention, Detection and Treatment. *Journal of Urology*, **2004**, 172, S3-5	2.5	4
99	Using molecular markers to predict outcome. *Journal of Urology*, **2004**, 172, S18-21; discussion S21-2	2.5	12
98	Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. *Cancer Research*, **2004**, 64, 2270-305	10.1	489
97	Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors. *Neoplasia*, **2004**, 6, 503-12	6.4	39
96	Elevated alpha-methylacyl-CoA racemase enzymatic activity in prostate cancer. *American Journal of Pathology*, **2004**, 164, 787-93	5.8	62
95	Quantitative determination of expression of the prostate cancer protein alpha-methylacyl-CoA racemase using automated quantitative analysis (AQUA): a novel paradigm for automated and continuous biomarker measurements. *American Journal of Pathology*, **2004**, 164, 831-40	5.8	135
94	Prospective evaluation of AMACR (P504S) and basal cell markers in the assessment of routine prostate needle biopsy specimens. *Human Pathology*, **2004**, 35, 1462-8	3.7	61
93	Postprostatectomy cancer-free survival of African Americans is similar to non-African Americans after adjustment for baseline cancer severity. *Urologic Oncology: Seminars and Original Investigations*, **2004**, 22, 20-4	2.8	25
92	Prostate needle biopsy reporting: how are the surgical members of the Society of Urologic Oncology using pathology reports to guide treatment of prostate cancer patients?. *American Journal of Surgical Pathology*, **2004**, 28, 946-52	6.7	91
91	Usefulness of basal cell cocktail (34betaE12 + p63) in the diagnosis of atypical prostate glandular proliferations. *American Journal of Clinical Pathology*, **2004**, 122, 517-23	1.9	14
90	Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. *Journal of the National Cancer Institute*, **2003**, 95, 661-8	9.7	220
89	Prevention of prostate cancer with finasteride. *New England Journal of Medicine*, **2003**, 349, 1569-72; author reply 1569-72	59.2	14
88	Basal cell cocktail (34betaE12 + p63) improves the detection of prostate basal cells. *American Journal of Surgical Pathology*, **2003**, 27, 365-71	6.7	118
87	Haploinsufficiency and reduced expression of genes localized to the 8p chromosomal region in human prostate tumors. *Genes Chromosomes and Cancer*, **2003**, 37, 306-13	5	18
86	Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. *Journal of Cellular Biochemistry*, **2003**, 89, 462-73	4.7	370
85	Dysregulation of the annexin family protein family is associated with prostate cancer progression. *American Journal of Pathology*, **2003**, 162, 255-61	5.8	149
84	Evaluation of the interobserver reproducibility of Gleason grading of prostatic adenocarcinoma using tissue microarrays. *Human Pathology*, **2003**, 34, 444-9	3.7	32

83	Contemporary preoperative parameters predict cancer-free survival after radical prostatectomy: a tool to facilitate treatment decisions. *Urologic Oncology: Seminars and Original Investigations*, **2003**, 21, 213-8	2.8	18
82	E-cadherin expression in primary carcinomas of the breast and its distant metastases. *Breast Cancer Research*, **2003**, 5, R217-22	8.3	280
81	Diagnostic Usefulness of Monoclonal Antibody P504S in the Workup of Atypical Prostatic Glandular Proliferations. *American Journal of Clinical Pathology*, **2003**, 120, 737-745	1.9	57
80	The role of calpain in the proteolytic cleavage of E-cadherin in prostate and mammary epithelial cells. *Journal of Biological Chemistry*, **2003**, 278, 1372-9	5.4	134
79	EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2003**, 100, 11606-11	11.5	1295
78	Diagnostic usefulness of monoclonal antibody P504S in the workup of atypical prostatic glandular proliferations. *American Journal of Clinical Pathology*, **2003**, 120, 737-45	1.9	5
77	Beta-catenin-related anomalies in apoptosis-resistant and hormone-refractory prostate cancer cells. *Clinical Cancer Research*, **2003**, 9, 1801-7	12.9	106
76	Expression profiling of human renal carcinomas with functional taxonomic analysis. *BMC Bioinformatics*, **2002**, 3, 26	3.6	39
75	Diagnosis of melanoma aspirates on ThinPrep: the University of Michigan experience. *Diagnostic Cytopathology*, **2002**, 26, 334-9	1.4	15
74	APC/CTNNB1 (beta-catenin) pathway alterations in human prostate cancers. *Genes Chromosomes and Cancer*, **2002**, 34, 9-16	5	133
73	The polycomb group protein EZH2 is involved in progression of prostate cancer. *Nature*, **2002**, 419, 624-9	30.4	2085
72	alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. *JAMA - Journal of the American Medical Association*, **2002**, 287, 1662-70	27.4	489
71	Comparison of the basal cell-specific markers, 34betaE12 and p63, in the diagnosis of prostate cancer. *American Journal of Surgical Pathology*, **2002**, 26, 1161-8	6.7	152
70	Mediastinal seminoma in a patient with Wiskott-Aldrich syndrome. *Journal of Pediatric Hematology/Oncology*, **2002**, 24, 672-6	1.2	4
69	Gene-expression profiles in hereditary breast cancer. *Advances in Anatomic Pathology*, **2002**, 9, 1-6	5.1	4
68	Tissue microarray sampling strategy for prostate cancer biomarker analysis. *American Journal of Surgical Pathology*, **2002**, 26, 312-9	6.7	258
67	Alpha-Methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions. *American Journal of Surgical Pathology*, **2002**, 26, 926-31	6.7	236
66	alpha-Methylacyl-CoA racemase: expression levels of this novel cancer biomarker depend on tumor differentiation. *American Journal of Pathology*, **2002**, 161, 841-8	5.8	105

65	Changes in differential gene expression because of warm ischemia time of radical prostatectomy specimens. *American Journal of Pathology*, **2002**, 161, 1743-8	5.8	124
64	Characterization of RhoC expression in benign and malignant breast disease: a potential new marker for small breast carcinomas with metastatic ability. *American Journal of Pathology*, **2002**, 160, 579-84	5.8	171
63	Tech.Sight. Understanding disease cell by cell. *Science*, **2002**, 296, 1329-30	33.3	27
62	Apoptosis and expression of Bcl-2, Bcl-XL, and Bax in renal cell carcinomas. *Cancer Investigation*, **2002**, 20, 324-32	2.1	82
61	Preoperative parameters for predicting early prostate cancer recurrence after radical prostatectomy. *Urology*, **2002**, 59, 740-5; discussion 745-6	1.6	38
60	Prostate cancer involving the bladder neck: recurrence-free survival and implications for AJCC staging modification. American Joint Committee on Cancer. *Urology*, **2002**, 60, 276-80	1.6	35
59	A functional thrombin receptor (PAR1) is expressed on bone-derived prostate cancer cell lines. *Urology*, **2002**, 60, 760-5	1.6	83
58	Inadequate formalin fixation decreases reliability of p27 immunohistochemical staining: probing optimal fixation time using high-density tissue microarrays. *Human Pathology*, **2002**, 33, 756-60	3.7	83
57	Huntingtin-interacting protein 1 is overexpressed in prostate and colon cancer and is critical for cellular survival. *Journal of Clinical Investigation*, **2002**, 110, 351-360	15.9	70
56	Huntingtin-interacting protein 1 is overexpressed in prostate and colon cancer and is critical for cellular survival. *Journal of Clinical Investigation*, **2002**, 110, 351-60	15.9	42
55	High-Density Tissue Microarray. *American Journal of Surgical Pathology*, **2002**, 26, 1237-1238	6.7	
54	High-density tissue microarray. *American Journal of Surgical Pathology*, **2002**, 26, 1236-8; discusson 1237-8	6.7	6
53	Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. *Cancer Research*, **2002**, 62, 4427-33	10.1	460
52	Delineation of prognostic biomarkers in prostate cancer. *Nature*, **2001**, 412, 822-6	50.4	1402
51	Prevalence and location of peripheral nerve found on prostate needle biopsy. *American Journal of Clinical Pathology*, **2001**, 115, 39-43	1.9	13
50	Loss of expression of human spectrin src homology domain binding protein 1 is associated with 10p loss in human prostatic adenocarcinoma. *Neoplasia*, **2001**, 3, 99-104	6.4	19
49	Relational database structure to manage high-density tissue microarray data and images for pathology studies focusing on clinical outcome: the prostate specialized program of research excellence model. *American Journal of Pathology*, **2001**, 159, 837-43	5.8	91
48	Postatrophic hyperplasia of the prostate gland: neoplastic precursor or innocent bystander?. *American Journal of Pathology*, **2001**, 158, 1767-73	5.8	112

47	Web-based tissue microarray image data analysis: initial validation testing through prostate cancer Gleason grading. *Human Pathology*, **2001**, 32, 417-27	3.7	48
46	E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology. *Human Pathology*, **2001**, 32, 690-7	3.7	150
45	Inferior vena cavectomy for nonexcisable Wilms' tumor thrombus. *Journal of Pediatric Surgery*, **2001** , 36, 526-9	2.6	12
44	Cure of undifferentiated small cell carcinoma of the urinary bladder with M-VAC chemotherapy. *Urologic Oncology: Seminars and Original Investigations*, **2001**, 6, 53-55	2.8	14
43	Analysis of three-dimensional ultrasound Doppler for the detection of prostate cancer. *Urology*, **2001**, 57, 1128-32	1.6	7
42	Profiling and verification of gene expression patterns in normal and malignant human prostate tissues by cDNA microarray analysis. *Neoplasia*, **2001**, 3, 43-52	6.4	86
41	Complete transurethral resection of bladder endocervicosis. *Journal of Urology*, **2001**, 165, 524	2.5	9
40	Predictors of Gleason pattern 4/5 prostate cancer on prostatectomy specimens: can high grade tumor be predicted preoperatively?. *Journal of Urology*, **2001**, 165, 114-8	2.5	44
39	Should a Gleason score be assigned to a minute focus of carcinoma on prostate biopsy?. *American Journal of Surgical Pathology*, **2000**, 24, 1634-40	6.7	44
38	Relationship and significance of greatest percentage of tumor and perineural invasion on needle biopsy in prostatic adenocarcinoma. *American Journal of Surgical Pathology*, **2000**, 24, 183-9	6.7	58
37	Prostatic neoplasia in transgenic mice with prostate-directed overexpression of the c-myc oncoprotein. *Prostate*, **2000**, 43, 278-85	4.2	59
36	Truncation of the beta-catenin binding domain of E-cadherin precedes epithelial apoptosis during prostate and mammary involution. *Journal of Biological Chemistry*, **2000**, 275, 3328-34	5.4	77
35	Tissue microarray assessment of prostate cancer tumor proliferation in African- American and white men. *Journal of the National Cancer Institute*, **2000**, 92, 937-9	9.7	62
34	Expression of nuclear antigen Ki-67 in prostate cancer needle biopsy and radical prostatectomy specimens. *Journal of the National Cancer Institute*, **2000**, 92, 1941-2	9.7	27
33	10q23.3 loss of heterozygosity is higher in lymph node-positive (pT2-3,N+) versus lymph node-negative (pT2-3,N0) prostate cancer. *Human Pathology*, **2000**, 31, 504-8	3.7	47
32	Neuroendocrine expression in metastatic prostate cancer: evaluation of high throughput tissue microarrays to detect heterogeneous protein expression. *Human Pathology*, **2000**, 31, 406-14	3.7	154
31	Bladder neck-sparing modification of radical prostatectomy adversely affects surgical margins in pathologic T3a prostate cancer. *Urology*, **2000**, 55, 904-8	1.6	46
30	Benign prostatic glands at surgical margins of radical prostatectomy specimens: frequency and associated risk factors. *Urology*, **2000**, 56, 721-5	1.6	39

29	WHOLE MOUNTED RADICAL PROSTATECTOMY SPECIMENS DO NOT INCREASE DETECTION OF ADVERSE PATHOLOGICAL FEATURES. *Journal of Urology*, **2000**, 164, 1583-1586	2.5	42
28	Prostatic neoplasia in transgenic mice with prostate-directed overexpression of the c-myc oncoprotein **2000**, 43, 278		2
27	Early effects of castration on the vascular system of the rat ventral prostate gland. *Endocrinology*, **1999**, 140, 1920-6	4.8	67
26	The detection of renal carcinoma cells in the peripheral blood with an enhanced reverse transcriptase-polymerase chain reaction assay for MN/CA9. *Cancer*, **1999**, 86, 492-7	6.4	51
25	Common mutations in BRCA1 and BRCA2 do not contribute to early prostate cancer in Jewish men. *Prostate*, **1999**, 40, 172-7	4.2	59
24	Perineural invasion on prostate needle biopsy: an independent predictor of final pathologic stage. *Urology*, **1999**, 54, 1039-43	1.6	77
23	Can perineural invasion on prostate needle biopsy predict prostate specific antigen recurrence after radical prostatectomy?. *Journal of Urology*, **1999**, 162, 103-6	2.5	64
22	Renal oncocytosis: a morphologic study of fourteen cases. *American Journal of Surgical Pathology*, **1999**, 23, 1094-101	6.7	176
21	MAXIMUM TUMOR DIMENSION PROVIDES A CLINICALLY USEFUL AND INDEPENDENTLY SIGNIFICANT MEASURE FOR PREDICTING PSA-FREE SURVIVAL FOLLOWING RADICAL PROSTATECTOMY. *Journal of Urology*, **1999**, 241	2.5	14
20	Cyclin D1 expression in human prostate carcinoma cell lines and primary tumors. *Prostate*, **1998**, 35, 95-101	4.2	63
19	Changes in biochemical disease-free survival rates as a result of adoption of the consensus conference definition in patients with clinically localized prostate cancer treated with external-beam radiotherapy. *International Journal of Radiation Oncology Biology Physics*, **1998**, 41, 511-7	4	27
18	Biologic classification as an alternative to anatomic staging for clinically localized prostate cancer: a proposal based on patients treated with external beam radiotherapy. *Urology*, **1998**, 51, 265-70	1.6	8
17	Cribriform carcinoma of the prostate and cribriform prostatic intraepithelial neoplasia: incidence and clinical implications. *American Journal of Surgical Pathology*, **1998**, 22, 840-8	6.7	100
16	Use of fine needle aspiration for solid breast lesions is accurate and cost-effective. *American Journal of Surgery*, **1997**, 174, 694-6; discussion 697-8	2.7	45
15	Abnormal prostate development in C3(1)-bcl-2 transgenic mice. *Prostate*, **1997**, 32, 16-26	4.2	30
14	Detection of circulating prostate carcinoma cells via an enhanced reverse transcriptase-polymerase chain reaction assay in patients with early stage prostate carcinoma. Independence from other pretreatment characteristics. *Cancer*, **1997**, 79, 2402-8	6.4	33
13	Intravascular large cell lymphoma coexisting within hemangiomas of the skin. *American Journal of Surgical Pathology*, **1997**, 21, 860-4	6.7	55
12	The role of the reverse-transcriptase polymerase chain reaction assay for prostate-specific antigen in the selection of patients for radical prostatectomy. *Urologic Clinics of North America*, **1996**, 23, 541-9	2.9	14

11	Giant malignant fibrous histiocytoma of the testis/spermatic cord: psychologic and possible etiologic complications of unethical Nazi medical experimentation. *Urology*, **1996**, 48, 939-43	1.6	18
10	H&E-stained Whole Slide Image Deep Learning Predicts SPOP Mutation State in Prostate Cancer		27
9	Discovery and reporting of clinically-relevant germline variants in advanced cancer patients assessed using whole-exome sequencing		2
8	Role of Specialized Composition of SWI/SNF Complexes in Prostate Cancer Lineage Plasticity		1
7	Patient-derived xenografts and organoids model therapy response in prostate cancer		1
6	The Genomic Landscape of Prostate Cancer Brain Metastases		2
5	Extracellular Microenvironment in Patient-derived Hydrogel Organoids of Prostate Cancer Regulates Therapeutic Response		2
4	Dual Functions of SPOP and ERG Dictate Androgen Therapy Responses in Prostate Cancer		1
3	Discovery and characterization of coding and non-coding driver mutations in more than 2,500 whole cancer genomes		12
2	Pathway and network analysis of more than 2,500 whole cancer genomes		4
1	The WHO 2022 landscape of papillary and chromophobe renal cell carcinoma. *Histopathology*,	7.3	0